{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T14:23:53Z","timestamp":1785680633703,"version":"3.56.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Glypican-3 (GPC3) is a membrane-bound heparan sulfate proteoglycan that functions in embryonic cell growth and differentiation and is highly expressed in the placenta. GPC3 is mutated in Simpson-Golabi-Behmel syndrome, which is characterized by tissue overgrowth and an increased risk of embryonal malignancies. GPC3 has also been implicated in sporadic cancer, particularly hepatocellular carcinoma, for which it has been shown to be a useful diagnostic marker. Although GPC3 expression has been studied in non-neoplastic placental tissue, its presence in gestational trophoblastic diseases has not been previously explored. The purpose of this study was to investigate the immunohistochemical expression of GPC3 in placental site trophoblastic tumor (PSTT), a very rare gestational trophoblastic neoplasm which may be morphologically confused with non-trophoblastic tumors, and to assess its possible utility as a diagnostic marker.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Fifteen cases of PSTT, as well as samples from placental site nodule (PSN) (n = 2), leiomyosarcoma (n = 1), leiomyoma (n = 1), invasive cervical squamous cell carcinoma (n = 7) and endometrial adenocarcinoma (n = 11) were examined. Immunoreactivity was semi-quantitatively evaluated as negative (0, &lt; 5% of cells stained), focally positive (1+, 5-10% of cells stained), positive (2+, 11-50% of cells stained) or diffusely positive (3+, &gt; 50% of cells stained). Staining intensity for each subtype was graded from 0 to 3 and a mean intensity was calculated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Eighty percent of PSTT (12\/15) were immunoreactive for GPC3 (0, 20; 1+, 20%; 2+, 40%; 3+, 20%) with a mean intensity of 1.3. Stronger, predominately cytoplasmic staining was seen in larger multi- and mononucleated cells with smaller mononucleate cells showing weak muddy cytoplasmic staining. Both PSN cases were positive (1+, 50%; 2+, 50%) and two of nine invasive cervical squamous cell carcinomas showed staining (0, 57%; 1+, 29%; 2+, 14%), predominately in a basal distribution. Other uterine tumors and non-neoplastic tissues were negative.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Identification of GPC3 in PSTT and PSN is consistent with the derivation of these lesions from intermediate trophoblasts, which have been described to express GPC3. GPC3 may be a useful adjunct immunohistochemical marker in differentiating PSTT from non-trophoblastic tumors.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1746-1596-5-64","type":"journal-article","created":{"date-parts":[[2010,9,25]],"date-time":"2010-09-25T06:13:51Z","timestamp":1285395231000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Expression of glypican 3 in placental site trophoblastic tumor"],"prefix":"10.1186","volume":"5","author":[{"given":"Robin J","family":"Ou-Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximing J","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra L","family":"Zynger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,9,25]]},"reference":[{"key":"309_CR1","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1146\/annurev.biochem.68.1.729","volume":"68","author":"M Bernfield","year":"1999","unstructured":"Bernfield M, G\u00f6tte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M: Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 1999, 68: 729-77. 10.1146\/annurev.biochem.68.1.729.","journal-title":"Annu Rev Biochem"},{"key":"309_CR2","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1054\/bjoc.2001.2054","volume":"85","author":"FH Blackhall","year":"2001","unstructured":"Blackhall FH, Merry CL, Davies EJ, Jayson GC: Heparan sulfate proteoglycans and cancer. Br J Cancer. 2001, 85: 1094-1098. 10.1054\/bjoc.2001.2054.","journal-title":"Br J Cancer"},{"key":"309_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1172\/JCI200113712","volume":"108","author":"J Filmus","year":"2001","unstructured":"Filmus J, Selleck SB: Glypicans: proteoglycans with a surprise. J Clin Invest. 2001, 108: 497-501.","journal-title":"J Clin Invest"},{"key":"309_CR4","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.1158\/0008-5472.CAN-04-4244","volume":"65","author":"MI Capurro","year":"2005","unstructured":"Capurro MI, Xiang YY, Lobe C, Filmus J: Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. 2005, 65: 6245-6254. 10.1158\/0008-5472.CAN-04-4244.","journal-title":"Cancer Res"},{"key":"309_CR5","first-page":"1333","volume":"23","author":"BV Iglesias","year":"2008","unstructured":"Iglesias BV, Centeno G, Pascuccelli H, Ward F, Peters MG, Filmus J, Puricelli L, de Kier Joff\u00e9 EB: Expression pattern of glypican-3 (GPC3) during human embryonic and fetal development. Histol Histopathol. 2008, 23: 1333-1340.","journal-title":"Histol Histopathol"},{"key":"309_CR6","first-page":"807","volume":"59","author":"H Lin","year":"1999","unstructured":"Lin H, Huber R, Schlessinger D, Morin PJ: Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res. 1999, 59: 807-810.","journal-title":"Cancer Res"},{"key":"309_CR7","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/1097-0215(20000920)89:5<418::AID-IJC4>3.0.CO;2-I","volume":"89","author":"Z Saikali","year":"2000","unstructured":"Saikali Z, Sinnett D: Expression of glypican 3 (GPC3) in embryonal tumors. Int J Cancer. 2000, 89: 418-422. 10.1002\/1097-0215(20000920)89:5<418::AID-IJC4>3.0.CO;2-I.","journal-title":"Int J Cancer"},{"key":"309_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/pgp.0b013e31802d692c","volume":"26","author":"S Stadlmann","year":"2007","unstructured":"Stadlmann S, Gueth U, Baumhoer D, Moch H, Terracciano L, Singer G: Glypican-3 expression in primary and recurrent ovarian carcinomas. Int J Gynecol Pathol. 2007, 26: 341-4. 10.1097\/pgp.0b013e31802d692c.","journal-title":"Int J Gynecol Pathol"},{"key":"309_CR9","doi-asserted-by":"publisher","first-page":"7408","DOI":"10.1038\/sj.onc.1204925","volume":"20","author":"YY Xiang","year":"2000","unstructured":"Xiang YY, Ladeda V, Filmus J: Glypican-3 expression is silenced in human breast cancer. Oncogene. 2000, 20: 7408-7412. 10.1038\/sj.onc.1204925.","journal-title":"Oncogene"},{"key":"309_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/ajmg.a.20279","volume":"122","author":"TL Gillan","year":"2003","unstructured":"Gillan TL, Hughes R, Godbout R, Grundy PE: The Simpson-Golabi-Behmel gene, GPC3, is not involved in sporadic Wilms tumorigenesis. Am J Med Genet A. 2003, 122: 30-36. 10.1002\/ajmg.a.20279.","journal-title":"Am J Med Genet A"},{"key":"309_CR11","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ijc.10856","volume":"103","author":"Y Midorikawa","year":"2003","unstructured":"Midorikawa Y, Ishikawa S, Iwanari H, Imamura T, Sakamoto H, Miyazono K, Kodama T, Makuuchi M, Aburatani H: Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer. 2003, 103: 455-465. 10.1002\/ijc.10856.","journal-title":"Int J Cancer"},{"key":"309_CR12","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1038\/modpathol.3800436","volume":"18","author":"N Yamauchi","year":"2005","unstructured":"Yamauchi N, Watanabe A, Hishinuma M, Ohashi K, Midorikawa Y, Morishita Y, Niki T, Shibahara J, Mori M, Makuuchi M, Hippo Y, Kodama T, Iwanari H, Aburatani H, Fukayama M: The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol. 2005, 18: 1591-8.","journal-title":"Mod Pathol"},{"key":"309_CR13","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.humpath.2007.06.006","volume":"39","author":"DL Zynger","year":"2008","unstructured":"Zynger DL, Gupta A, Luan C, Chou PM, Yang GY, Yang XJ: Expression of glypican 3 in hepatoblastoma: an immunohistochemical study of 65 cases. Hum Pathol. 2008, 39: 224-30. 10.1016\/j.humpath.2007.06.006.","journal-title":"Hum Pathol"},{"key":"309_CR14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1242\/dev.128.1.87","volume":"128","author":"GH Baeg","year":"2001","unstructured":"Baeg GH, Lin X, Khare N, Baumgartner S, Perrimon N: Heparan sulfate proteoglycans are critical for the organization of the extracellular distribution of Wingless. Development. 2001, 128: 87-94.","journal-title":"Development"},{"key":"309_CR15","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1006\/gyno.2001.6356","volume":"82","author":"IM Shih","year":"2001","unstructured":"Shih IM, Kurman RJ: Placental site trophoblastic tumor--past as prologue. Gynecol Oncol. 2001, 82: 413-414. 10.1006\/gyno.2001.6356.","journal-title":"Gynecol Oncol"},{"key":"309_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00432-007-0208-y","volume":"134","author":"N Behtash","year":"2008","unstructured":"Behtash N, Zarchi MK: Placental site trophoblastic tumor. J Cancer Res Clin Oncol. 2008, 134: 1-6. 10.1007\/s00432-007-0208-y.","journal-title":"J Cancer Res Clin Oncol"},{"key":"309_CR17","first-page":"897","volume":"2","author":"M Bower","year":"1996","unstructured":"Bower M, Paradinas FJ, Fisher RA, Nicholson SK, Rustin GJ, Begent RH, Bagshawe KD, Newlands ES: Placental site trophoblastic tumor: molecular analysis and clinical experience. Clin Cancer Res. 1996, 2: 897-902.","journal-title":"Clin Cancer Res"},{"key":"309_CR18","first-page":"71","volume":"16","author":"S Khan","year":"2001","unstructured":"Khan S, Blackburn M, Mao DL, Huber R, Schlessinger D, Fant M: Glypican-3 (GPC3) expression in human placenta: localization to the differentiated syncytiotrophoblast. Histol Histopathol. 2001, 16: 71-78.","journal-title":"Histol Histopathol"},{"key":"309_CR19","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1097\/01.pas.0000213322.89670.48","volume":"30","author":"DL Zynger","year":"2006","unstructured":"Zynger DL, Dimov ND, Luan C, Teh BT, Yang XJ: Glypican 3: a novel marker in testicular germ cell tumors. Am J Surg Pathol. 2006, 30: 1570-1575. 10.1097\/01.pas.0000213322.89670.48.","journal-title":"Am J Surg Pathol"},{"key":"309_CR20","doi-asserted-by":"publisher","first-page":";308","DOI":"10.1007\/s00428-006-0238-x","volume":"449","author":"S Ota","year":"2006","unstructured":"Ota S, Hishinuma M, Yamauchi N, Goto A, Morikawa T, Fujimura T, Kitamura T, Kodama T, Aburatani H, Fukayama M: Oncofetal protein glypican-3 in testicular germ-cell tumor. Virchows Arch. 2006, 449: ;308-314. 10.1007\/s00428-006-0238-x.","journal-title":"Virchows Arch"},{"key":"309_CR21","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1309\/8DN7DQRDFB4QNH3N","volume":"130","author":"DL Zynger","year":"2008","unstructured":"Zynger DL, Everton MJ, Dimov ND, Chou PM, Yang XJ: Expression of glypican 3 in ovarian and extragonadal germ cell tumors. Am J Clin Pathol. 2008, 130: 224-30. 10.1309\/8DN7DQRDFB4QNH3N.","journal-title":"Am J Clin Pathol"},{"key":"309_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1006\/scdb.2000.0240","volume":"12","author":"B De Cat","year":"2001","unstructured":"De Cat B, David G: Developmental roles of the glypicans. Semin Cell Dev Biol. 2001, 12: 117-125. 10.1006\/scdb.2000.0240.","journal-title":"Semin Cell Dev Biol"},{"key":"309_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/ng0396-241","volume":"12","author":"G Pilia","year":"1996","unstructured":"Pilia G, Hughes-Benzie RM, MacKenzie A, Baybayan P, Chen EY, Huber R, Neri G, Cao A, Forabosco A, Schlessinger D: Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet. 1996, 12: 241-247. 10.1038\/ng0396-241.","journal-title":"Nat Genet"},{"key":"309_CR24","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.devcel.2008.03.006","volume":"14","author":"MI Capurro","year":"2008","unstructured":"Capurro MI, Xu P, Shi W, Li F, Jia A, Filmus J: Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Dev Cell. 2008, 14: 700-11. 10.1016\/j.devcel.2008.03.006.","journal-title":"Dev Cell"},{"key":"309_CR25","doi-asserted-by":"publisher","first-page":"7574","DOI":"10.1074\/jbc.272.12.7574","volume":"272","author":"HH Song","year":"1997","unstructured":"Song HH, Shi W, Filmus J: OCI-5\/rat glypican-3 binds to fibroblast growth factor-2 but not to insulin-like growth factor-2. J Biol Chem. 1997, 272: 7574-7577. 10.1074\/jbc.272.12.7574.","journal-title":"J Biol Chem"},{"key":"309_CR26","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1074\/jbc.M410090200","volume":"280","author":"HH Song","year":"2005","unstructured":"Song HH, Shi W, Xiang YY, Filmus J: The loss of glypican-3 induces alterations in Wnt signaling. J Biol Chem. 2005, 280: 2116-2125. 10.1074\/jbc.M410090200.","journal-title":"J Biol Chem"},{"key":"309_CR27","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1042\/bj3270577","volume":"327","author":"AE Mast","year":"1997","unstructured":"Mast AE, Higuchi DA, Huang ZF, Warshawsky I, Schwartz AL, Broze GJ: Glypican-3 is a binding protein on the HepG2 cell surface for tissue factor pathway inhibitor. Biochem J. 1997, 327: 577-583.","journal-title":"Biochem J"},{"key":"309_CR28","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/ajmg.1320430165","volume":"43","author":"RM Hughes-Benzie","year":"1992","unstructured":"Hughes-Benzie RM, Hunter AG, Allanson JE, Mackenzie AE: Simpson-Golabi-Behmel syndrome associated with renal dysplasia and embryonal tumor: localization of the gene to Xqcen-q21. Am J Med Genet. 1992, 43: 428-435. 10.1002\/ajmg.1320430165.","journal-title":"Am J Med Genet"},{"key":"309_CR29","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/hmg\/9.9.1321","volume":"9","author":"M Veugelers","year":"2000","unstructured":"Veugelers M, Cat BD, Muyldermans SY, Reekmans G, Delande N, Frints S, Legius E, Fryns JP, Schrander-Stumpel C, Weidle B, Magdalena N, David G: Mutational analysis of the GPC3\/GPC4 glypican gene cluster on Xq26 in patients with Simpson-Golabi-Behmel syndrome: identification of loss-of-function mutations in the GPC3 gene. Hum Mol Genet. 2000, 9: 1321-1328. 10.1093\/hmg\/9.9.1321.","journal-title":"Hum Mol Genet"},{"key":"309_CR30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/jmg.35.2.153","volume":"35","author":"P Lapunzina","year":"1998","unstructured":"Lapunzina P, Badia I, Galoppo C, De Matteo E, Silberman P, Tello A, Grichener J, Hughes-Benzie R: A patient with Simpson-Golabi-Behmel syndrome and hepatocellular carcinoma. J Med Genet. 1998, 35: 153-156. 10.1136\/jmg.35.2.153.","journal-title":"J Med Genet"},{"key":"309_CR31","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1136\/gut.48.4.558","volume":"48","author":"ZW Zhu","year":"2001","unstructured":"Zhu ZW, Friess H, Wang L, Abou-Shady M, Zimmermann A, Lander AD, Korc M, Kleeff J, B\u00fcchler MW: Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut. 2001, 48: 558-564. 10.1136\/gut.48.4.558.","journal-title":"Gut"},{"key":"309_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S0006-291X(03)00908-2","volume":"306","author":"T Nakatsura","year":"2003","unstructured":"Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, Hosaka S, Beppu T, Ishiko T, Kamohara H, Ashihara H, Katagiri T, Furukawa Y, Fujiyama S, Ogawa M, Nakamura Y, Nishimura Y: Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun. 2003, 306: 16-25. 10.1016\/S0006-291X(03)00908-2.","journal-title":"Biochem Biophys Res Commun"},{"key":"309_CR33","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/PAS.0b013e318158142f","volume":"32","author":"WM Coston","year":"2008","unstructured":"Coston WM, Loera S, Lau SK, Ishizawa S, Jiang Z, Wu CL, Yen Y, Weiss LM, Chu PG: Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry. Am J Surg Pathol. 2008, 32: 433-44. 10.1097\/PAS.0b013e318158142f.","journal-title":"Am J Surg Pathol"},{"key":"309_CR34","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.placenta.2006.01.023","volume":"28","author":"M Ogawa","year":"2007","unstructured":"Ogawa M, Yanoma S, Nagashima Y, Okamoto N, Ishikawa H, Haruki A, Miyagi E, Takahashi T, Hirahara F, Miyagi Y: Paradoxical discrepancy between the serum level and the placental intensity of PP5\/TFPI-2 in preeclampsia and\/or intrauterine growth restriction: possible interaction and correlation with glypican-3 hold the key. Placenta. 2007, 28: 224-232. 10.1016\/j.placenta.2006.01.023.","journal-title":"Placenta"},{"key":"309_CR35","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1365-2559.2008.03045.x","volume":"53","author":"L Pantanowitz","year":"2008","unstructured":"Pantanowitz L, Otis CN: Glypican-3 immunohistochemistry in the ovary. Histopathol. 2008, 53: 115-117. 10.1111\/j.1365-2559.2008.03045.x.","journal-title":"Histopathol"},{"key":"309_CR36","first-page":"484","volume":"58","author":"TV Ajithkumar","year":"2003","unstructured":"Ajithkumar TV, Abraham EK, Rejnishkumar R, Minimole AL: Placental site trophoblastic tumor. Obstet Gynecol Surv. 2003, 58: 484-488.","journal-title":"Obstet Gynecol Surv"},{"key":"309_CR37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/00004347-200101000-00004","volume":"20","author":"IM Shih","year":"2001","unstructured":"Shih IM, Kurman RJ: The pathology of intermediate trophoblastic tumors and tumor-like lesions. Int J Gynecol Pathol. 2001, 20: 31-47. 10.1097\/00004347-200101000-00004.","journal-title":"Int J Gynecol Pathol"},{"key":"309_CR38","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1097\/PAS.0b013e318191f2eb","volume":"33","author":"N Kalhor","year":"2009","unstructured":"Kalhor N, Ramirez PT, Deavers MT, Malpica A, Silva EG: Immunohistochemical studies of trophoblastic tumors. Am J Surg Pathol. 2009, 33: 633-638. 10.1097\/PAS.0b013e318191f2eb.","journal-title":"Am J Surg Pathol"},{"key":"309_CR39","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1097\/PAS.0b013e318058a529","volume":"31","author":"TL Mao","year":"2007","unstructured":"Mao TL, Kurman RJ, Huang CC, Lin MC, Shih IeM: Immunohistochemistry of choriocarcinoma: an aid in differential diagnosis and in elucidating pathogenesis. Am J Surg Pathol. 2007, 31: 1726-32. 10.1097\/PAS.0b013e318058a529.","journal-title":"Am J Surg Pathol"},{"key":"309_CR40","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1097\/00000478-200207000-00010","volume":"26","author":"G Singer","year":"2002","unstructured":"Singer G, Kurman RJ, McMaster MT, Shih IM: HLA-G immunoreactivity is specific for intermediate trophoblast in gestational trophoblastic disease and can serve as a useful marker in differential diagnosis. Am J Surg Pathol. 2002, 26: 914-20. 10.1097\/00000478-200207000-00010.","journal-title":"Am J Surg Pathol"},{"key":"309_CR41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0046-8177(98)90386-0","volume":"29","author":"IM Shih","year":"1998","unstructured":"Shih IM, Kurman RJ: Ki-67 labeling index in the differential diagnosis of exaggerated placental site, placental site trophoblastic tumor, and choriocarcinoma: a double immunohistochemical staining technique using Ki-67 and Mel-CAM antibodies. Hum Pathol. 1998, 29: 27-33. 10.1016\/S0046-8177(98)90386-0.","journal-title":"Hum Pathol"},{"key":"309_CR42","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1309\/HCQWPWD50XHD2DW6","volume":"129","author":"D Baumhoer","year":"2008","unstructured":"Baumhoer D, Tornillo L, Stadlmann S, Roncalli M, Diamantis EK, Terracciano LM: Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues. Am J Clin Pathol. 2008, 129: 899-905. 10.1309\/HCQWPWD50XHD2DW6.","journal-title":"Am J Clin Pathol"},{"key":"309_CR43","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1158\/0008-5472.CAN-03-2191","volume":"64","author":"Y Hippo","year":"2004","unstructured":"Hippo Y, Watanabe K, Watanabe A, Midorikawa Y, Yamamoto S, Ihara S, Tokita S, Iwanari H, Ito Y, Nakano K, Nezu J, Tsunoda H, Yoshino T, Ohizumi I, Tsuchiya M, Ohnishi S, Makuuchi M, Hamakubo T, Kodama T, Aburatani H: Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res. 2004, 64: 2418-2423. 10.1158\/0008-5472.CAN-03-2191.","journal-title":"Cancer Res"},{"key":"309_CR44","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0016-5085(03)00689-9","volume":"125","author":"M Capurro","year":"2003","unstructured":"Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J: Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003, 125: 89-97. 10.1016\/S0016-5085(03)00689-9.","journal-title":"Gastroenterology"},{"key":"309_CR45","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.bbrc.2008.11.033","volume":"378","author":"K Nakano","year":"2009","unstructured":"Nakano K, Orita T, Nezu J, Yoshino T, Ohizumi I, Sugimoto M, Furugaki K, Kinoshita Y, Ishiguro T, Hamakubo T, Kodama T, Aburatani H, Yamada-Okabe H, Tsuchiya M: Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2009, 378: 279-84. 10.1016\/j.bbrc.2008.11.033.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1746-1596-5-64.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T04:26:32Z","timestamp":1630470392000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/1746-1596-5-64"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,25]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["309"],"URL":"https:\/\/doi.org\/10.1186\/1746-1596-5-64","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,25]]},"assertion":[{"value":"6 September 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"64"}}